UBS Sticks to Its Hold Rating for Edwards Lifesciences (EW)

UBS analyst Danielle Antalffy reiterated a Hold rating on Edwards Lifesciences on October 6 and set a price target of $85.00. The company’s shares closed yesterday at $76.72.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Antalffy is a 3-star analyst with an average return of 2.6% and a 51.43% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Dexcom.

Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $88.92.

EW market cap is currently $44.95B and has a P/E ratio of 52.38.

Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year. Most recently, in July 2025, Daniel J. Lippis, the CVP, JAPAC of EW sold 4,114.00 shares for a total of $326,898.44.